Validation of dosimetry programs (Olinda & IDAC) for evaluation of absorbed dose in ¹⁷⁷LuPSMA therapy of metastatic castration-resistant prostate cancer (mCRPC) using Monte Carlo simulation.

ABSTRACT:

Purpose

Clinical trials have yielded promising results for ¹⁷⁷Lutetium Prostate Specific Membrane Antigen (¹⁷⁷Lu-PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC) patients. However, the development of precise methods for internal dosimetry and accurate dose estimation has been considered ongoing research. This study aimed to calculate the absorbed dose to the critical organs and metastasis regions using GATE 9.0 Monte Carlo simulation (MCS) as a gold standard to compare the OLINDA 1.1 and IDAC 2.1 software.

Material and methods

This study investigated absorbed doses to different organs in 9 mCRPC patients during their first treatment cycle. Whole-body planar images were acquired at 1 ± 0.5, 4 ± 0.5, 24 ± 2, 48 ± 2, 72 ± 2, and 144

SUBMITTER: Maroufpour S 

PROVIDER: S-EPMC11612135 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature